| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
35,530,000 |
| Market
Cap: |
327.59(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.43 - $11.75 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Mind Medicine Mindmed is a clinical stage biopharmaceutical company developing products to treat brain health disorders, with a focus on psychiatry, addiction, pain and neurology. Co.'s drug candidates include: MM-120, which is a proprietary, pharmaceutically optimized form of lysergide, and is being developed for the treatment of generalized anxiety disorder; MM-110, which is its proprietary form of 18-methoxycoronaridine, a congener of ibogaine, that is being developed for the treatment of opioid withdrawal; and MM-402, which is its proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine, that is developed for the treatment of main symptoms of autism spectrum disorder.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
23,097 |
48,760 |
128,859 |
371,715 |
| Total Sell Value |
$219,422 |
$312,579 |
$590,703 |
$862,273 |
| Total People Sold |
2 |
3 |
3 |
3 |
| Total Sell Transactions |
2 |
5 |
12 |
38 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Karlin Dan |
Chief Medical Officer |
• – – |
2024-03-25 |
4 |
AS |
$9.50 |
$62,491 |
D/D |
(6,578) |
358,452 |
|
-4% |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2024-03-25 |
4 |
AS |
$9.50 |
$156,931 |
D/D |
(16,519) |
580,202 |
|
-4% |
|
| Greenway Schond L. |
Chief Financial Officer |
• – – |
2024-03-25 |
4 |
D |
$9.78 |
$54,377 |
D/D |
(5,560) |
211,057 |
|
- |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2023-12-26 |
4 |
S |
$3.63 |
$24,590 |
D/D |
(6,774) |
365,030 |
|
-158% |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2023-12-26 |
4 |
S |
$3.63 |
$48,050 |
D/D |
(13,237) |
596,721 |
|
-158% |
|
| Greenway Schond L. |
Chief Financial Officer |
• – – |
2023-12-26 |
4 |
S |
$3.63 |
$20,517 |
D/D |
(5,652) |
216,617 |
|
-158% |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2023-09-25 |
4 |
S |
$3.57 |
$24,730 |
D/D |
(6,918) |
371,804 |
|
-13% |
|
| Greenway Schond L. |
Chief Financial Officer |
• – – |
2023-09-25 |
4 |
S |
$3.57 |
$20,609 |
D/D |
(5,762) |
222,269 |
|
-13% |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2023-09-25 |
4 |
S |
$3.57 |
$48,274 |
D/D |
(13,499) |
611,729 |
|
-13% |
|
| Greenway Schond L. |
Chief Financial Officer |
• – – |
2023-08-25 |
4 |
S |
$3.80 |
$76,000 |
D/D |
(20,000) |
228,031 |
|
-1% |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2023-06-27 |
4 |
S |
$3.19 |
$49,620 |
D/D |
(15,502) |
623,457 |
|
17% |
|
| Greenway Schond L. |
Chief Financial Officer |
• – – |
2023-06-27 |
4 |
S |
$3.19 |
$37,194 |
D/D |
(11,635) |
248,031 |
|
17% |
|
| Karlin Dan |
Chief Medical Officer |
• – – |
2023-06-27 |
4 |
S |
$3.19 |
$21,697 |
D/D |
(6,783) |
378,722 |
|
17% |
|
| Gryska David W |
Director |
– • – |
2023-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
13,851 |
13,851 |
|
- |
|
| Vallone Carol A |
Director |
– • – |
2023-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
13,671 |
16,544 |
|
- |
|
| Krebs Andreas |
Director |
– • – |
2023-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
13,671 |
15,107 |
|
- |
|
| Crystal Roger |
Director |
– • – |
2023-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
13,671 |
19,623 |
|
- |
|
| Bruhn Suzanne Louise |
Director |
– • – |
2023-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
13,671 |
19,623 |
|
- |
|
| Sullivan Mark |
Chief Legal Officer |
• – – |
2023-04-13 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
200,000 |
|
- |
|
| Liao Carrie |
Chief Accounting Officer |
• – – |
2023-03-14 |
4/A |
A |
$0.00 |
$0 |
D/D |
75,000 |
101,895 |
|
- |
|
| Greenway Schond L. |
Chief Financial Officer |
• – – |
2023-03-14 |
4/A |
A |
$0.00 |
$0 |
D/D |
175,000 |
259,666 |
|
- |
|
| Wernli Miri Halperin |
Executive President |
• • – |
2023-03-14 |
4/A |
A |
$0.00 |
$0 |
D/D |
100,000 |
185,000 |
|
- |
|
| Wernli Miri Halperin |
Executive President |
• • – |
2023-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
1,375,000 |
|
- |
|
| Greenway Schond L. |
Chief Financial Officer |
• – – |
2023-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
175,000 |
1,445,000 |
|
- |
|
| Barrow Robert |
Chief Executive Officer |
• • – |
2023-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
400,000 |
638,959 |
|
- |
|
79 Records found
|
|
Page 1 of 4 |
|
|
0.78 (7.8%) 
